COMPARE · Data as of August 14, 2026
ETON vs GRFS
Verdict: Side-by-side breakdown using the Bull Rankings model. ETON scored 72.0, GRFS scored 70.9 — ETON leads.
Compare another set
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
Score gap
1.1
ETON leads
GRFS
Grifols, S.A.
70.9
$7.78 · $5.3B
The model, pillar by pillar (0–100 each)
ETON
stronger →← stronger
GRFS
76
Qualityreturns · margins · balance sheet
56
100
Growthrevenue & earnings expansion
77
50
Valuevaluation vs sector peers
96
ETON is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ETON
GRFS
$15mC-
FCF
$563mC+
+81.5%A
Rev
+9.4%B
1.02C
D/E
1.17C
150.9xD
P/E
10.2xA
1.40B
PEG
0.19A
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ETON
GRFS
335% above
Price vs fair valuelower is cheaper
50% below
~54%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-5%/yr
-83%
1-yr DCF upside
+60%
-77%
5-yr DCF upside
+100%
-65%
10-yr DCF upside
+175%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ETON
Why this score
- Short track record
GRFS
Why this score
- Raising its dividend
- Foreign reporter (EUR)
The companies
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.69 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
GRFSGrifols, S.A.
Why now
Drug Manufacturers - General · market cap $5.3b. Down 28% from 52-week high of $10.77 — deep drawdown territory. PEG 0.19 — paying under fair value for the growth rate.
Moat
FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ETON and GRFS diverge
On the headline score the gap is 1.1 points in favor of ETON. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueETON 50.0 · GRFS 96.4GRFS +46.4
- GrowthETON 100.0 · GRFS 77.0ETON +23.0
- QualityETON 75.6 · GRFS 56.0ETON +19.6
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.